JP2017526662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526662A5 JP2017526662A5 JP2017506390A JP2017506390A JP2017526662A5 JP 2017526662 A5 JP2017526662 A5 JP 2017526662A5 JP 2017506390 A JP2017506390 A JP 2017506390A JP 2017506390 A JP2017506390 A JP 2017506390A JP 2017526662 A5 JP2017526662 A5 JP 2017526662A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- compound
- pharmaceutically acceptable
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 47
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 28
- 239000003207 proteasome inhibitor Substances 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 19
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 229940125904 compound 1 Drugs 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 208000034578 Multiple myelomas Diseases 0.000 claims description 12
- 229960001467 bortezomib Drugs 0.000 claims description 12
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 12
- 229960002438 carfilzomib Drugs 0.000 claims description 12
- 108010021331 carfilzomib Proteins 0.000 claims description 12
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229950002736 marizomib Drugs 0.000 claims description 11
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 claims description 11
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 201000010536 head and neck cancer Diseases 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 229960003648 ixazomib Drugs 0.000 claims description 6
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 201000002628 peritoneum cancer Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 206010046766 uterine cancer Diseases 0.000 claims description 6
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 5
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 5
- 108010064641 ONX 0912 Proteins 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 5
- 229950005750 oprozomib Drugs 0.000 claims description 5
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 5
- 230000005907 cancer growth Effects 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 230000000405 serological effect Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229950001466 delanzomib Drugs 0.000 claims 2
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims 2
- -1 Opurozomibu Chemical compound 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 201000009030 Carcinoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033386P | 2014-08-05 | 2014-08-05 | |
| US62/033,386 | 2014-08-05 | ||
| PCT/US2015/043825 WO2016022697A1 (en) | 2014-08-05 | 2015-08-05 | Drug combinations to treat multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186703A Division JP2020002179A (ja) | 2014-08-05 | 2019-10-10 | 多発性骨髄腫を治療するための薬物の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526662A JP2017526662A (ja) | 2017-09-14 |
| JP2017526662A5 true JP2017526662A5 (OSRAM) | 2018-09-06 |
| JP6892381B2 JP6892381B2 (ja) | 2021-06-23 |
Family
ID=53836256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506390A Active JP6892381B2 (ja) | 2014-08-05 | 2015-08-05 | 多発性骨髄腫を治療するための薬物の組み合わせ |
| JP2019186703A Pending JP2020002179A (ja) | 2014-08-05 | 2019-10-10 | 多発性骨髄腫を治療するための薬物の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186703A Pending JP2020002179A (ja) | 2014-08-05 | 2019-10-10 | 多発性骨髄腫を治療するための薬物の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11065240B2 (OSRAM) |
| EP (1) | EP3177311B1 (OSRAM) |
| JP (2) | JP6892381B2 (OSRAM) |
| KR (1) | KR102634247B1 (OSRAM) |
| CN (1) | CN106573042A (OSRAM) |
| AU (1) | AU2015301097B2 (OSRAM) |
| BR (1) | BR112017002318A2 (OSRAM) |
| CA (1) | CA2957466C (OSRAM) |
| EA (1) | EA034992B1 (OSRAM) |
| MA (1) | MA40457A (OSRAM) |
| MX (1) | MX382904B (OSRAM) |
| UA (1) | UA121482C2 (OSRAM) |
| WO (1) | WO2016022697A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| AU2015301097B2 (en) | 2014-08-05 | 2021-03-04 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
| CA3020749A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| CA3075714A1 (en) * | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| EP4647127A3 (en) | 2018-01-26 | 2025-12-17 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| WO2019241504A1 (en) | 2018-06-15 | 2019-12-19 | Handa Pharmaceuticals, Llc | Kinase inhibitor salts and compositions thereof |
| WO2023222946A1 (en) | 2022-05-18 | 2023-11-23 | Fermion Oy | Process for the preparation of cabozantinib |
| EP4658271A1 (en) | 2023-01-31 | 2025-12-10 | Handa Oncology, LLC | Improved cabozantinib compositions and methods of use |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6402215B1 (en) * | 1996-05-21 | 2002-06-11 | American Moto Products, Inc. | Vehicle cargo bed extender |
| ES2925655T3 (es) | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
| AU2005270068B2 (en) | 2004-07-02 | 2012-04-19 | Exelixis, Inc. | C-Met modulators and method of use |
| WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| TR201900306T4 (tr) | 2006-12-14 | 2019-02-21 | Exelixis Inc | Mek inhibitörlerini kullanma yöntemleri. |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
| TW201022258A (en) | 2008-11-13 | 2010-06-16 | Exelixis Inc | Methods of preparing quinoline derivatives |
| WO2010065838A1 (en) | 2008-12-04 | 2010-06-10 | Exelixis, Inc. | Methods of preparing quinoline derivatives |
| KR20250123237A (ko) | 2009-01-16 | 2025-08-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| MX2012000809A (es) | 2009-07-17 | 2012-03-14 | Exelixis Inc | Formas cristalinas de n-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin- 4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclop ropan-1,1-dicarboxamida. |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| BR112012019302B1 (pt) * | 2010-02-03 | 2022-06-21 | Incyte Holdings Corporation | Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula |
| TW201202228A (en) | 2010-03-12 | 2012-01-16 | Exelixis Inc | Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
| WO2012009723A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| AU2011278950C1 (en) | 2010-07-16 | 2018-11-22 | Exelixis, Inc. | c-Met modulator pharmaceutical compositions |
| SI2621481T2 (sl) | 2010-09-27 | 2023-02-28 | Exelixis, Inc., | Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz |
| CA2812753A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| EP2621483A1 (en) | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
| WO2012071321A1 (en) | 2010-11-22 | 2012-05-31 | Glaxosmithkline Llc | Method of treating cancer |
| AU2012214322B2 (en) | 2011-02-10 | 2017-04-27 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| JP2014513129A (ja) | 2011-05-02 | 2014-05-29 | エクセリクシス， インク． | 癌および骨癌疼痛の治療方法 |
| TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| US10166225B2 (en) | 2011-09-22 | 2019-01-01 | Exelixis, Inc. | Method for treating osteoporosis |
| US9365516B2 (en) | 2011-10-20 | 2016-06-14 | Exelixis, Inc. | Process for preparing quinoline derivatives |
| WO2013070890A1 (en) | 2011-11-08 | 2013-05-16 | Exelixis, Inc. | Dual inhibitor of met and vegf for treating cancer |
| CA2863986A1 (en) * | 2012-02-06 | 2013-08-15 | The Regents Of The University Of California | Emp2 regulates angiogenesis in cancer cells through induction of vegf |
| CN103304552B (zh) * | 2012-03-09 | 2016-12-28 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
| HK1207587A1 (en) | 2012-05-02 | 2016-02-05 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN114129566A (zh) | 2012-09-07 | 2022-03-04 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
| US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
| AU2014232714B2 (en) | 2013-03-15 | 2018-07-19 | Exelixis, Inc. | Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| AU2014248001A1 (en) | 2013-04-04 | 2015-11-19 | Exelixis, Inc. | Drug combinations to treat cancer |
| US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
| AR100191A1 (es) | 2014-04-25 | 2016-09-14 | Exelixis Inc | Método para tratar adenocarcinoma de pulmón |
| EP3174854B1 (en) | 2014-07-31 | 2022-08-24 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
| AU2015301097B2 (en) | 2014-08-05 | 2021-03-04 | Exelixis, Inc. | Drug combinations to treat multiple myeloma |
| TW201625243A (zh) | 2014-10-14 | 2016-07-16 | 艾克塞里克斯公司 | 用於治療黑素瘤之藥物組合 |
-
2015
- 2015-08-05 AU AU2015301097A patent/AU2015301097B2/en active Active
- 2015-08-05 JP JP2017506390A patent/JP6892381B2/ja active Active
- 2015-08-05 MX MX2017001490A patent/MX382904B/es unknown
- 2015-08-05 EP EP15750223.8A patent/EP3177311B1/en active Active
- 2015-08-05 CN CN201580042010.4A patent/CN106573042A/zh active Pending
- 2015-08-05 BR BR112017002318-0A patent/BR112017002318A2/pt active Search and Examination
- 2015-08-05 KR KR1020177006288A patent/KR102634247B1/ko active Active
- 2015-08-05 EA EA201790312A patent/EA034992B1/ru not_active IP Right Cessation
- 2015-08-05 US US15/501,582 patent/US11065240B2/en active Active
- 2015-08-05 CA CA2957466A patent/CA2957466C/en active Active
- 2015-08-05 MA MA040457A patent/MA40457A/fr unknown
- 2015-08-05 UA UAA201702039A patent/UA121482C2/uk unknown
- 2015-08-05 WO PCT/US2015/043825 patent/WO2016022697A1/en not_active Ceased
-
2019
- 2019-10-10 JP JP2019186703A patent/JP2020002179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526662A5 (OSRAM) | ||
| JP2012153722A5 (OSRAM) | ||
| JP2011515397A5 (OSRAM) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| EA201690322A1 (ru) | Терапевтически активные соединения и способы их применения | |
| JP2015536964A5 (OSRAM) | ||
| JP2010241830A5 (OSRAM) | ||
| JP2016522266A5 (OSRAM) | ||
| JP2016501221A5 (OSRAM) | ||
| JP2016519062A5 (OSRAM) | ||
| JP2010523670A5 (OSRAM) | ||
| JP2010001302A5 (OSRAM) | ||
| JP2014533299A5 (OSRAM) | ||
| JP2016503414A5 (OSRAM) | ||
| JP2017528475A5 (OSRAM) | ||
| JP2015509540A5 (OSRAM) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2015512943A5 (OSRAM) | ||
| RU2011124894A (ru) | Триазолотиадиазоловый ингибитор протеинкиназы с-мет | |
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания | |
| JP2019534865A5 (OSRAM) | ||
| JP2017507175A5 (OSRAM) | ||
| JP2014509653A5 (OSRAM) | ||
| JP2011516536A5 (OSRAM) |